PSTX insider transaction filings
Poseida Therapeutics, Inc. — 29 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-01-10. Screen PSTX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for PSTX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Poseida Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-01-10 | 4 | Malin Life Sciences Holdings Ltd — 10% owner | Code (U): 11,835,673 | EDGAR |
| 2025-01-08 | 4 | Amado Rafael — Director | Code (U): 58,950 · Disposition to issuer (D): 55,200 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Corning Luke — Director | Code (U): 58,950 · Disposition to issuer (D): 45,833 (derivative) @ $0 · Disposition to issuer (D): 28,500 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Mylet Johanna — Chief Financial Officer | Code (U): 254,852 · Disposition to issuer (D): 4,117 (derivative) @ $0 · Disposition to issuer (D): 80,192 (derivative) @ $0 · Disposition to issuer (D): 35,000 (derivative) @ $0 · Disposition to issuer (D): 82,000 (derivative) @ $0 · Disposition to issuer (D): 65,000 (derivative) @ $0 · +3 more | EDGAR |
| 2025-01-08 | 4 | Rizvi Syed Ali-aamir — Chief Medical Officer | Code (U): 185,000 · Disposition to issuer (D): 250,000 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Yarema Kristin — President and CEO | Code (U): 615,836 · Disposition to issuer (D): 498,325 (derivative) @ $0 · Disposition to issuer (D): 345,200 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | BAUM CHARLES M — Director | Code (U): 78,600 · Disposition to issuer (D): 57,000 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Schmid John P. — Director | Code (U): 58,950 · Disposition to issuer (D): 32,076 (derivative) @ $0 · Disposition to issuer (D): 16,038 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 25,833 (derivative) @ $0 · +3 more | EDGAR |
| 2025-01-08 | 4 | Collins Cynthia — Director | Code (U): 58,950 · Disposition to issuer (D): 87,440 (derivative) @ $0 · Disposition to issuer (D): 28,500 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | LEONHARDT HARRY J — GC & Chief Compliance Officer | Code (U): 223,640 · Disposition to issuer (D): 160,385 (derivative) @ $0 · Disposition to issuer (D): 137,000 (derivative) @ $0 · Disposition to issuer (D): 72,568 (derivative) @ $0 · Disposition to issuer (D): 125,283 (derivative) @ $0 · Disposition to issuer (D): 111,700 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Lloyd Marcea Bland — Director | Code (U): 68,950 · Disposition to issuer (D): 32,076 (derivative) @ $0 · Disposition to issuer (D): 16,038 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 25,833 (derivative) @ $0 · +3 more | EDGAR |
| 2025-01-08 | 4 | Gergen Mark J — President and CEO, Director | Code (U): 636,726 · Disposition to issuer (D): 240,721 (derivative) @ $0 · Disposition to issuer (D): 48,115 (derivative) @ $0 · Disposition to issuer (D): 75,000 (derivative) @ $0 · Disposition to issuer (D): 342,000 (derivative) @ $0 · Disposition to issuer (D): 518,500 (derivative) @ $0 · +2 more | EDGAR |
| 2025-01-03 | 4 | Gergen Mark J — Executive Chairman, Director | Tax withholding (F): 23,313 @ $9.60 | EDGAR |
| 2024-12-11 | 4 | Gergen Mark J — Executive Chairman, Director | Option exercise (M): 30,000 @ $2.78 · Sale (S): 30,000 @ $9.46 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | Gergen Mark J — Executive Chairman, Director | Option exercise (M): 30,000 @ $2.78 · Sale (S): 30,000 @ $9.27 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Corning Luke — Director | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Amado Rafael — Director | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BAUM CHARLES M — Director | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Schmid John P. — Director | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Collins Cynthia — Director | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Lloyd Marcea Bland — Director | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Rizvi Syed Ali-aamir — Chief Medical Officer | Grant/award (A): 185,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Mylet Johanna — Chief Financial Officer | Grant/award (A): 80,743 @ $0 · Tax withholding (F): 18,091 @ $4.13 · Grant/award (A): 111,700 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Warner Brent — President, Gene Therapy | Grant/award (A): 80,743 @ $0 · Tax withholding (F): 35,739 @ $4.13 · Grant/award (A): 111,700 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Gergen Mark J — Executive Chairman, Director | Tax withholding (F): 34,157 @ $4.13 | EDGAR |
| 2024-03-04 | 4 | LEONHARDT HARRY J — GC & Chief Compliance Officer | Grant/award (A): 80,743 @ $0 · Tax withholding (F): 16,306 @ $4.13 · Grant/award (A): 111,700 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Gergen Mark J — Executive Chairman, Director | Tax withholding (F): 47,162 @ $3.41 | EDGAR |
| 2024-01-04 | 4 | Yarema Kristin — President and CEO, Director | Grant/award (A): 250,000 @ $0 · Grant/award (A): 345,200 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Gergen Mark J — Executive Chairman, Director | Grant/award (A): 125,000 @ $0 · Grant/award (A): 172,600 (derivative) @ $0 | EDGAR |
Recent 8-K events — Poseida Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-01-08 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2024-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2024-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-17 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PSTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →